US price-fixing litigation targeting Teva has been selected as a priority for trial, making it a “bellwether” case, as part of the wider ongoing US investigation into generic price-fixing allegations.
The decision by a district court for the eastern district of Pennsylvania came shortly after a third major price-fixing lawsuit was filed in the US in June, focusing mainly on topical drugs. (Also see "Third Price-Fixing Lawsuit Filed In US" - Generics Bulletin, 11 June, 2020